NCT03726658View on ClinicalTrials.gov

AGN-241751 in the Treatment of Major Depressive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

November 8, 2018

Primary Completion Date

October 23, 2019

Study Completion Date

October 23, 2019

Conditions
Major Depressive Disorder
Interventions
DRUG

AGN-241751

AGN-241751 is supplied in tablet form

DRUG

Placebo

Placebo is supplied in tablet form

Trial Locations (5)

30331

Atlanta Center for Medical Research, Atlanta

85012

Alea Research, Phoenix

92845

Collaborative Neuroscience Network, LLC, Garden Grove

98007

Northwest Clinical Research Center, Bellevue

08809

Hassman Research Institute, Berlin

All Listed Sponsors
lead

Syndeio Biosciences, Inc

INDUSTRY

NCT03726658 - AGN-241751 in the Treatment of Major Depressive Disorder | Biotech Hunter | Biotech Hunter